Emergingby GlyphNanobiotix prices an oversubscribed EUR 85M global offering
Gross proceeds reached about $100M after the over-allotment was exercised.
sec.gov
Nanotechnology
Early commercialmomentum 266,053 papers a year (+32%)$171M raised in 12 months16 companies
Engineering matter at the scale of atoms and molecules, from drug-carrying nanoparticles to tiny molecular machines.
Why early commercial: The EU approved KOSTAIVE, a self-amplifying mRNA vaccine using Arcturus's LUNAR lipid-mediated delivery, in February 2025. Feb 14, 2025
Dots under a month: dated events tracked here that month.
Events
All 16 eventsFirst randomized Phase 2 data for JNJ-1900 in stage 3 lung cancer
Johnson & Johnson presented the data at the 2026 European Lung Cancer Conference.
sec.gov
Lipid nanoparticles engineered to deliver RNA to the pancreas
A Nature study reaches pancreatic cells that LNPs could not reach before.
nature.com
Acuitas takes a majority stake in RNA Technologies & Therapeutics
The LNP supplier adds mRNA construct design and manufacturing expertise.
acuitastx.com
XOMA Royalty agrees to acquire Generation Bio
The deal brings Generation Bio's cell-targeted LNP platform into XOMA's portfolio.
sec.gov
Funding
Nanobiotix
$100MSource ↗
Nanobiotix
Led by HealthCare Royalty
$71MSource ↗
ReCode Therapeutics
$29MSource ↗
Companies
All 16 companiesNanobiotix
Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900.
nanobiotix.com
Johnson & Johnson
Licenses and runs global development of Nanobiotix's NBTXR3 nanoparticle as JNJ-1900.
jnj.com
Acuitas Therapeutics
Supplies lipid nanoparticle delivery systems to partners developing nucleic acid drugs.
acuitastx.com
Generation Bio
Developed cell-targeted lipid nanoparticles for siRNA; agreed to be acquired by XOMA Royalty.
generationbio.com
XOMA Royalty
Royalty aggregator that agreed to buy Generation Bio and its ctLNP platform.
xoma.com
AbbVie
Bought Capstan's in vivo tLNP CAR-T program for $2.1 billion in cash.
abbvie.com
Researchers and labs
All 63 researchers and labsYi-Xiang Wang
Publishes on Nanotechnology at BGI Group (China): 19 papers in 2 years.
Yue Wang
Publishes on Nanotechnology at BGI Group (China): 25 papers in 2 years.
Prashant Kesharwani
Publishes on Nanotechnology at Chandigarh University: 56 papers in 2 years.
Zhonggui He
Publishes on Nanotechnology at Shenyang Pharmaceutical University: 51 papers in 2 years.
Center for Nanoscale Science and Technology
Runs the NanoFab, giving researchers access to nanoscale fabrication tools.
Center for Nanoscience and Nanotechnology
Home of Dan Peer's group working on targeted RNA-LNP delivery.
Most cited papers
All 50 papersEffects of nanoparticle size, shape, and zeta potential on drug delivery
Kıvılcım Öztürk, Meryem Kaplan, Sema Çalış · International Journal of Pharmaceutics
Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect
Chengcheng Feng, Yuting Wang, Yuting Wang et al. · Pharmaceutics
A translational framework to DELIVER nanomedicines to the clinic
Paul Joyce, Christine J. Allen, Marı́a José Alonso et al. · Nature Nanotechnology
Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape
Nimeet Desai, Dhwani Rana, Mitali Patel et al. · Small
Advances in nanoparticles in targeted drug delivery–A review
Safiul Islam, Md Mir Shakib Ahmed, Mohammad Aminul Islam et al. · Results in Surfaces and Interfaces
Patents
Cancer vaccines
ModernaTx Inc
Lipids for lipid nanoparticle delivery of active agents
Acuitas Therapeutics Inc
Cationic lipid compounds for use in lipid nanoparticles
Acuitas Therapeutics Inc
Coronavirus vaccine
Biontech SE
Coronavirus vaccine
Biontech SE
Coronavirus rna vaccines
ModernaTx Inc
About nanotechnology here
- Sub-areas
- Lipid nanoparticle deliveryNanomedicineNanomaterialsMolecular machinesDNA nanotechnologyAtomically precise manufacturing
- Stage evidence
- Early commercial, Feb 14, 2025: The EU approved KOSTAIVE, a self-amplifying mRNA vaccine using Arcturus's LUNAR lipid-mediated delivery, in February 2025. newsroom.csl.com
- Momentum
- 26 of 100: the mean of its ranks among the tracked fields for paper growth (63), funding in 12 months (13) and events in 90 days (3). Method
- Papers
- 6,053 in the 12 months ending two months ago, +32% against the 12 before (OpenAlex topics, journal and conference papers).
- Tracked here since
- Sep 25, 2026
- Weekly snapshots
- 5 weeks stored; latest Nov 2, 2026. JSON
Changes to this field
Nanotechnology
Tracked from here on: Engineering matter at the scale of atoms and molecules, from drug-carrying nanoparticles to tiny molecular machines.